伊普塔科潘在异常性免疫复杂介导的膜增殖性淋巴结膜炎:APPARENT多中心,随机的第三阶段研究的协议
Marina Vivarelli1, Andrew S Bomback2, Matthias Meier3
1Division of Nephrology, Laboratory of Nephrology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Kidney international reports
|February 5, 2024
概括
伊普塔科潘在治疗罕见的病方面表现有前途. 这项研究对iptacopan进行了评估.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫复合体介导的膜增殖性球腺炎 (IC-MPGN) 是一种罕见的,侵袭性的病,没有向治疗.
- 替代补充路径的调节失调是IC-MPGN病原体的核心.
- 伊普塔科潘是一种口服补充抑制剂,向替代途径.
研究的目的:
- 评估伊普塔科潘在患有异常性IC-MPGN的患者中的疗效和安全性.
- 评估伊普塔科潘对蛋白尿和功能的影响.
主要方法:
- 一项随机,双盲,安慰剂控制的第三阶段研究 (APPARENT) 涉及68名患者 (12-60岁),其活检证实IC-MPGN.
- 患者接受了最大耐受度的ACE抑制剂/ARB和细菌疫苗接种.
- 参与者被随机分配给六个月的伊普塔科潘 (每天两次200毫克) 或安慰剂,随后是所有人的开放标签伊普塔科潘.
主要成果:
- 主要终点是6个月后蛋白尿减少 (尿蛋白与肌素的比率).
- 二级终点包括估计的淋巴细胞过率 (eGFR) 的变化和患者报告的疲劳.
- 该研究将提供关于伊普塔科潘在该患者群体中的有效性和安全性的证据.
结论:
- 这项研究旨在为伊普塔科潘在治疗异常性IC-MPGN时的有效性和安全性提供关键证据.
- 结果将为这种极为罕见的病提供潜在的新治疗策略.
相关概念视频
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
842
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
842
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
559
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559